Their DNBSEQ-Tx sequencing factory, with dip-immersion reagent delivery and 4 high-throughput imagers, can produce >50K WGS annually. Technology being upgraded from PE100 to PE150 (2021Q3)
A presentation from a user shows how #singlecell 10X Genomics libraries can be inputted into the MGI machines. Small difference between FASTQ files, but tools available to transform.
After that, then back to DNBSEQ CoolMPS technology. Main difference to Illumina is that there is essentially no Index Hopping, due to the nature of the affixed position in the patterned flowcells, and also low duplication rates.
The CoolMPS sequencing technique is based on anibodies, with low signal loss due to "Scarless synthesis".
End of this month or next month will be the official release of the new longer Paired-End kits
• • •
Missing some Tweet in this thread? You can try to
force a refresh
More highlights of the prospectus for $ONT.L Oxford @nanopore, now concentrating on more technical aspects.
Aiming for a 4-5x step change in throughput between the different product lines: 126/512 ~ 4x and 512/2675 ~ 5x between Flongle / MinION / PromethION
There are a lots of other details that matter here, but it gives us a rough estimate of multiples between product throughput and how the company thinks about them. Compared to Illumina, their MiSeq/NextSeq/NovaSeq ratios are:
15/360 ~ 24x and 360/6000 ~ 16x, but with ...
Gross Margin of 30% is a single number encompassing a lot of different costs inside. My first guess is that the ASICs part of the technology has a lot of margin in volume and alternatives.a
Also, a starter pack can be more costly as it contains added elements that are helpful for starting customers, but it slims down to basics for regular customers.
Finally, and this is pure speculative territory, the tech slide of the flexible small-printer ASIC POC shows a path forward to make Oxford @nanopore independent from large suppliers of semiconductor materials produced by large specialised FABs.
A few notes (in no particular order) on the Oxford @nanopore 30-Sep-2021 document timed for their IPO (data.fca.org.uk/artefacts/NSM/…) (1) The importance of GPUs and SSDs as part of the computational equipment perceived to be needed now and in the near/mid term future
They only mention competitors by name in stating the difference between synthesis-based sequencing and the nanopore approach. They mention Illumina and PacBio later on in patent litigation risks but not too interesting.
Their TAM and potential TAM slide is probably the most insightful: reiterating what the company always said about long-reads, ubiquitous and fast TAT products and the markets they can disrupt with these
In #biotech#stocks, more market jitters at NASDAQ opening, all biotech stocks down except for $ONT.L Oxford @nanopore and $NEO NeoGenomics
$ONT.L Oxford @nanopore floated on Wednesday, today still on a steady uphill. Trades in London stock exchange, so off by 4-5 hours US East time.
$NEO NeoGenomics has been on a tear in the last few days. A company growing both organically and by acquisition, aggressively positioning itself in the #LiquidBiopsy#CancerScreening segment.
In #biotech#stocks, the highlight today is $ONT.L Oxford @nanopore which now has its own stock ticker in the London Stock Market. Yahoo Finance hasn't updated the Market Cap yet, I think it usually takes a few days. Google Finance has no matches for it yet.
I've added it to my list between $NTRA (~$10B) and $NVTA (~$6B). Assuming it holds above $6B by the time the market cap value shows up in Yahoo Finance, that's the right place for the stock to be.
This now adds $6B of market cap to my list, which after a few jittery days at the NASDAQ, is at around $440-$450B, with the 4 largest #biotechs holding about 2/3rds of the value.
Another twitter thread on (#NGS) technologies, this time focussing on Oxford @nanopore. The company sells their larger instrument, the PromethION, which has some advantages/limitations over other competing technologies:
The advantages of the PromethION are mainly (1) the read length of Oxford Nanopore's technology, which depending on the sample prep method, can go over several megabases, and (2) it's a high-throughput instrument that can run up to 48 individual flowcells, at the lowest cost.
Another major advantage of the technology is that it's not limited to a 4-letter alphabet of unmodified A,C,G,T, but can also natively basecall commonly epigenetic modifications, such as 5mC (methylation) and others, making the use for epigenomic profiling very straightforward.